ELAN Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 9.32%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Corcept Therapeutics, Inc.'s return on equity of 16%.

Elanco Animal Health, Inc. has a consensus price target of $24.08, signalling upside risk potential of 9.52%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $135.25 which suggests that it could grow by 59.76%. Given that Corcept Therapeutics, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Elanco Animal Health, Inc..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Elanco Animal Health, Inc.'s net income of -$34M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 301.65x while Corcept Therapeutics, Inc.'s PE ratio is 96.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.38x versus 13.66x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 24.85%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

Elanco Animal Health, Inc. has a consensus price target of $24.08, signalling upside risk potential of 9.52%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $759.00 which suggests that it could grow by 5.79%. Given that Elanco Animal Health, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Elanco Animal Health, Inc. is more attractive than IDEXX Laboratories, Inc..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are larger than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Elanco Animal Health, Inc.'s net income of -$34M is lower than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 301.65x while IDEXX Laboratories, Inc.'s PE ratio is 56.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.38x versus 14.04x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 31.72%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Eli Lilly & Co.'s return on equity of 106.26%.

Elanco Animal Health, Inc. has a consensus price target of $24.08, signalling upside risk potential of 9.52%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Elanco Animal Health, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Elanco Animal Health, Inc. is more attractive than Eli Lilly & Co..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 301.65x while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.38x versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 30.04%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Zoetis, Inc.'s return on equity of 52.95%.

Elanco Animal Health, Inc. has a consensus price target of $24.08, signalling upside risk potential of 9.52%. On the other hand Zoetis, Inc. has an analysts' consensus of $165.36 which suggests that it could grow by 37.03%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.841%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.63% to investors and pays a quarterly dividend of $0.50 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Zoetis, Inc.'s net income of $721M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 301.65x while Zoetis, Inc.'s PE ratio is 20.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.38x versus 5.83x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.